TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06418360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack
Description: 10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
Study: NCT06257186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
Study: NCT00705796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPP10, testosterone
Description: Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: AndroGel® 50 mg, once daily in the morning after washing/showering.
Study: NCT05797857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
Study: NCT06232759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Description: Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
Study: NCT04954209

Intervention type: OTHER
Intervention: Physical activities in hospital
Description: 3 month in a resumption program of physical activity in hospital

Intervention type: OTHER
Intervention: Physical activity outside hospital
Description: 3 month in a resumption program of physical activity outside hospital with discovery sessions
Study: NCT05841706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)
Description: Receive conservative transfusion strategy (Hgb \< 7 g/dL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)
Description: Receive liberal transfusion strategy (Hgb \< 9 g/dL)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: surgical removal of all or part of pancreas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: surgical removal of all or part of pancreas
Study: NCT05020860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Description: Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
Study: NCT05224518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: elastic band training
Description: elastic band training include stretching exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: elastic band training
Description: elastic band training include stretching exercises
Study: NCT06476301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
Study: NCT06475547

Intervention type: OTHER
Intervention: Descriptive
Description: This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.
Study: NCT04816734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Description: Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home.
Study: NCT06578754

Intervention type: OTHER
Intervention: This is an non-interventional study
Description: Only blood samples will be required in this study. It is noninterventional.

Intervention type: OTHER
Intervention: This is an non-interventional study
Description: Only blood samples will be required in this study. It is noninterventional.

Intervention type: OTHER
Intervention: This is an non-interventional study
Description: Only blood samples will be required in this study. It is noninterventional.

Intervention type: OTHER
Intervention: This is an non-interventional study
Description: Only blood samples will be required in this study. It is noninterventional.
Study: NCT04690322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eloctate
Description: Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adynovate
Description: Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
Study: NCT04931758

Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7

Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
Study: NCT06390423

Intervention type: DIAGNOSTIC_TEST
Intervention: Passive leg raise, SVI via bioreactance, Echo based VTI
Description: No interventions other than fluid challenge
Study: NCT05920707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Arginine Vasopressin
Description: Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
Study: NCT05627388

Intervention type: OTHER
Group type: OTHER
Intervention: Dreem 3 System At-Home Monitoring
Description: Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
Study: NCT05139901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: inhalations twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: inhalations twice daily
Study: NCT05863182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Juntos Familia Family based intervention
Description: Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
Study: NCT05096026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PCP Outreach
Description: These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored PCP Outreach
Description: These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
Study: NCT05632809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV (vein)
Study: NCT05724576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmniMSC-AMI
Description: 10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
Study: NCT04793412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Cochlear implantation of a device from one of the three manufacturers available in the US.
Study: NCT04318249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Relaxation Therapy
Description: This intervention includes using a smartphone application that helps with breathing techniques and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Relaxation Therapy
Description: This intervention includes using a smartphone application that helps with breathing techniques and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Assisted Relaxation Therapy
Description: This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
Study: NCT06328543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
Study: NCT04672577

Intervention type: OTHER
Intervention: Observational study
Description: No intervention is planned
Study: NCT04801303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood analysis for frataxin's level measurement
Description: 1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~* Age- and gender-matched controls (supposedly non-heterozygous).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood analysis for hypercalcemia's control
Description: Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
Study: NCT06328543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study: NCT05488743

Intervention type: BEHAVIORAL
Intervention: educational intervention
Description: The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
Study: NCT04760977

Intervention type: DRUG
Intervention: Drugs administration
Description: Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents

Intervention type: DEVICE
Intervention: Resuscitative endovascular balloon occlusion of the aorta
Description: Resuscitative technique for exsanguinating traumas

Intervention type: BIOLOGICAL
Intervention: Blood transfusions
Description: Transfuion of transported blood products for exsanguinating traumas

Intervention type: OTHER
Intervention: Prehospital management
Description: Stay and play strategy vs scoop and run

Intervention type: DEVICE
Intervention: Prehospital eFAST
Description: Prehospital thorax/abdomen extended focused assessment sonography for trauma
Study: NCT05273528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study: NCT04584801

Intervention type: DEVICE
Intervention: Structured Light Plethysmography
Description: Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment

Intervention type: DEVICE
Intervention: Structured Light Plethysmography
Description: Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment
Study: NCT05951413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol
Description: estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: estradiol
Description: estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
Study: NCT06353464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ensure and Water
Description: Ensure, a liquid meal with 9 grams of protein in 8 ounces consumed 20 minutes before eating pizza; and water, 8 ounces consumed 20 minutes before eating pizza
Study: NCT06068062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modification of OSCE using TBL format
Description: Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
Study: NCT05990374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
Study: NCT05538286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearFit implant
Description: The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial ultrasonography through sonolucent cranioplasty
Description: The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
Study: NCT05151172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy (EVT)
Description: minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
Study: NCT05990374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
Study: NCT05151172

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standarad medical care
Description: Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
Study: NCT05652686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT217
Description: A bispecific antibody (bsAb) against DLL3 and CD47.
Study: NCT05652686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT217
Description: A bispecific antibody (bsAb) against DLL3 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT217
Description: A bispecific antibody (bsAb) against DLL3 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT217
Description: A bispecific antibody (bsAb) against DLL3 and CD47.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Etoposide
Description: Administered per Standard of Care.
Study: NCT05990374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
Description: The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
Study: NCT05652686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Etoposide
Description: Administered per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel.
Description: Administered per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered per Standard of Care.